TW200834074A - A method for evaluating the ability of a test compound to reduce a level of Aβ in vivo and an in vitro method for predicting an increased likelihood of amyloidosis in a subject - Google Patents
A method for evaluating the ability of a test compound to reduce a level of Aβ in vivo and an in vitro method for predicting an increased likelihood of amyloidosis in a subjectInfo
- Publication number
- TW200834074A TW200834074A TW097114203A TW97114203A TW200834074A TW 200834074 A TW200834074 A TW 200834074A TW 097114203 A TW097114203 A TW 097114203A TW 97114203 A TW97114203 A TW 97114203A TW 200834074 A TW200834074 A TW 200834074A
- Authority
- TW
- Taiwan
- Prior art keywords
- ovx
- levels
- brain
- vivo
- guinea pigs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 2
- 206010002022 amyloidosis Diseases 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 210000004556 brain Anatomy 0.000 abstract 4
- 241000700198 Cavia Species 0.000 abstract 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 abstract 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- 230000003942 amyloidogenic effect Effects 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000009806 oophorectomy Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16381999P | 1999-11-05 | 1999-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200834074A true TW200834074A (en) | 2008-08-16 |
Family
ID=22591720
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097114203A TW200834074A (en) | 1999-11-05 | 2001-02-16 | A method for evaluating the ability of a test compound to reduce a level of Aβ in vivo and an in vitro method for predicting an increased likelihood of amyloidosis in a subject |
| TW095101005A TWI302099B (en) | 1999-11-05 | 2001-02-16 | A method for evaluating the ability of a test compound to reduce a ratio of aβ42 to aβ40 in vivo |
| TW089123307A TWI265026B (en) | 1999-11-05 | 2001-02-16 | Pharmaceutical composition for reducing amyloid-beta(Abeta) peptide |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095101005A TWI302099B (en) | 1999-11-05 | 2001-02-16 | A method for evaluating the ability of a test compound to reduce a ratio of aβ42 to aβ40 in vivo |
| TW089123307A TWI265026B (en) | 1999-11-05 | 2001-02-16 | Pharmaceutical composition for reducing amyloid-beta(Abeta) peptide |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080085244A1 (https=) |
| EP (1) | EP1272853A2 (https=) |
| JP (2) | JP2003522737A (https=) |
| AR (1) | AR027878A1 (https=) |
| AU (2) | AU2005200176B2 (https=) |
| CA (1) | CA2390161A1 (https=) |
| MX (1) | MXPA02004480A (https=) |
| NZ (3) | NZ518780A (https=) |
| TW (3) | TW200834074A (https=) |
| WO (1) | WO2001035106A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
| US20020173499A1 (en) * | 2001-03-16 | 2002-11-21 | Wyeth | Estrogen replacement therapy |
| US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| US20130203722A1 (en) | 2006-09-26 | 2013-08-08 | Rhonda R. Voskuhl | Estriol therapy for autoimmune and neurodegenerative disease and disorders |
| US8658627B2 (en) | 2001-04-25 | 2014-02-25 | The Regents Of The University Of California | Pregnancy hormone combination for treatment of autoimmune diseases |
| EP1371986A1 (en) * | 2002-06-06 | 2003-12-17 | ABETA GmbH | Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio |
| JP2007284351A (ja) * | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2698167A3 (en) * | 2005-09-26 | 2014-03-05 | The Regents of The University of California | Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4311870C2 (de) * | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| JP3552272B2 (ja) * | 1994-05-27 | 2004-08-11 | 帝国臓器製薬株式会社 | 免疫化学的簡易アッセイ方法および装置 |
| WO1997046664A1 (en) * | 1996-06-06 | 1997-12-11 | University Of Washington | Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses |
| JPH1090261A (ja) * | 1996-08-23 | 1998-04-10 | Fuotoreru Patrick | 性ステロイドホルモン測定用プレート、これを用いた測定キット及び測定法 |
| US5898094A (en) * | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
| WO1998043647A1 (en) * | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
| AU7260398A (en) * | 1997-04-28 | 1998-11-24 | University Of British Columbia, The | Method and composition for modulating amyloidosis |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
-
2000
- 2000-11-01 AR ARP000105767A patent/AR027878A1/es unknown
- 2000-11-03 AU AU2005200176A patent/AU2005200176B2/en not_active Ceased
- 2000-11-03 JP JP2001536585A patent/JP2003522737A/ja active Pending
- 2000-11-03 AU AU14592/01A patent/AU779781B2/en not_active Ceased
- 2000-11-03 CA CA002390161A patent/CA2390161A1/en not_active Abandoned
- 2000-11-03 MX MXPA02004480A patent/MXPA02004480A/es not_active Application Discontinuation
- 2000-11-03 NZ NZ518780A patent/NZ518780A/en unknown
- 2000-11-03 EP EP00976880A patent/EP1272853A2/en not_active Withdrawn
- 2000-11-03 NZ NZ543850A patent/NZ543850A/en unknown
- 2000-11-03 WO PCT/US2000/030310 patent/WO2001035106A2/en not_active Ceased
- 2000-11-03 NZ NZ536461A patent/NZ536461A/en unknown
-
2001
- 2001-02-16 TW TW097114203A patent/TW200834074A/zh unknown
- 2001-02-16 TW TW095101005A patent/TWI302099B/zh not_active IP Right Cessation
- 2001-02-16 TW TW089123307A patent/TWI265026B/zh not_active IP Right Cessation
-
2007
- 2007-11-01 JP JP2007285586A patent/JP2008058329A/ja active Pending
- 2007-12-07 US US11/952,531 patent/US20080085244A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1272853A2 (en) | 2003-01-08 |
| AU2005200176A1 (en) | 2005-02-10 |
| TWI265026B (en) | 2006-11-01 |
| JP2008058329A (ja) | 2008-03-13 |
| NZ518780A (en) | 2006-02-24 |
| NZ543850A (en) | 2009-03-31 |
| TWI302099B (en) | 2008-10-21 |
| TW200621221A (en) | 2006-07-01 |
| US20080085244A1 (en) | 2008-04-10 |
| AU1459201A (en) | 2001-06-06 |
| AR027878A1 (es) | 2003-04-16 |
| MXPA02004480A (es) | 2004-09-10 |
| AU2005200176B2 (en) | 2007-10-25 |
| NZ536461A (en) | 2005-02-25 |
| CA2390161A1 (en) | 2001-05-17 |
| AU779781B2 (en) | 2005-02-10 |
| WO2001035106A2 (en) | 2001-05-17 |
| JP2003522737A (ja) | 2003-07-29 |
| WO2001035106A3 (en) | 2002-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luczynski et al. | Adult microbiota‐deficient mice have distinct dendritic morphological changes: differential effects in the amygdala and hippocampus | |
| DE60045427D1 (de) | Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen | |
| MXPA03005721A (es) | Uso novedoso de artemina, un miembro de la familia de ligandos gdnf. | |
| FR12C0008I2 (fr) | Compositions et methodes permettant de stabiliser la transthyretine et d'inhiber un mauvais repliement de la transthyretine | |
| AR036401A1 (es) | Incremento de la cantidad de celulas madre neuronales inducido por prolactina. | |
| TW200834074A (en) | A method for evaluating the ability of a test compound to reduce a level of Aβ in vivo and an in vitro method for predicting an increased likelihood of amyloidosis in a subject | |
| MA29966B1 (fr) | Traitement des tumeurs neuroendocrines | |
| ATE544460T1 (de) | Zusammensetzungen und verfahren für eine gesunde schwangerschaft | |
| EA200200847A1 (ru) | Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов | |
| EA200300027A1 (ru) | Способ лечения сердечно-сосудистых заболеваний | |
| NO20076241L (no) | Terapier for vaskulaere sykdommer | |
| Freitas et al. | Catalase activity in cerebellum, hippocampus, frontal cortex and striatum after status epilepticus induced by pilocarpine in Wistar rats | |
| Lockrow et al. | A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model | |
| EA200800879A1 (ru) | Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов | |
| TW200505409A (en) | Methods of inhibiting neurodegenerative disease | |
| BRPI0417674A (pt) | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 | |
| Castillo-Mariqueo et al. | Indexes for flotation and circling, two non-search behaviors in the water maze, sensitive to D-galactose–induced accelerated aging and Alzheimer’s disease | |
| WO2004006856A3 (en) | Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression | |
| DE60204067D1 (de) | Verwendung von Xanthenon-4-Essigsäure zur Herstellung eines Medikaments für die Behandlung von hyperproliferativer Störungen | |
| MXPA03010406A (es) | Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd. | |
| DE69721747D1 (de) | Methode zur behandlung oder verhütung von interstitieller blasenentzundung | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| ATE410172T1 (de) | Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes | |
| EP1628663A4 (en) | METHOD FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLIOSIS | |
| WO2004016751A3 (en) | Methods of treating neurodegenerative diseases |